[HTML][HTML] Exatecan antibody drug conjugates based on a hydrophilic polysarcosine drug-linker platform
L Conilh, G Fournet, E Fourmaux, A Murcia, EL Matera… - Pharmaceuticals, 2021 - mdpi.com
We herein report the development and evaluation of a novel HER2-targeting antibody–drug
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
L Conilh, G Fournet, E Fourmaux… - Pharmaceuticals …, 2021 - pubmed.ncbi.nlm.nih.gov
We herein report the development and evaluation of a novel HER2-targeting antibody-drug
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
[PDF][PDF] Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
L Conilh, G Fournet, E Fourmaux… - …, 2021 - pdfs.semanticscholar.org
We herein report the development and evaluation of a novel HER2-targeting antibody–drug
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
[PDF][PDF] Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
L Conilh, G Fournet, E Fourmaux, A Murcia… - …, 2021 - academia.edu
We herein report the development and evaluation of a novel HER2-targeting antibody–drug
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
G Fournet, L Conilh, E Fourmaux, A Murcia… - …, 2021 - hal.science
We herein report the development and evaluation of a novel HER2-targeting antibody–drug
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform.
L Conilh, G Fournet, E Fourmaux, A Murcia… - Pharmaceuticals …, 2021 - europepmc.org
We herein report the development and evaluation of a novel HER2-targeting antibody–drug
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform.
L Conilh, G Fournet, E Fourmaux… - Pharmaceuticals …, 2021 - search.ebscohost.com
We herein report the development and evaluation of a novel HER2-targeting antibody–drug
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
L Conilh, G Fournet, E Fourmaux, A Murcia… - …, 2021 - search.proquest.com
We herein report the development and evaluation of a novel HER2-targeting antibody–drug
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
L Conilh, G Fournet, E Fourmaux, A Murcia… - …, 2021 - cir.nii.ac.jp
抄録< jats: p> We herein report the development and evaluation of a novel HER2-targeting
antibody–drug conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan …
antibody–drug conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan …
[PDF][PDF] Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
L Conilh, G Fournet, E Fourmaux, A Murcia… - …, 2021 - researchgate.net
We herein report the development and evaluation of a novel HER2-targeting antibody–drug
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …